Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ese and other risks are described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward looking statements because of these uncertainties, and the inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. We assume no obligation to update forward looking statements. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G

Table 1

Amicus Therapeutics, Inc.

(a development stage company)

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

Period

from

February 4,

2002

(inception)

Three Months to

Ended March 31, March 31,

2007 2008 2008

Revenue:

Research revenue $- $2,466 $ 3,841

Collaboration revenue - 694 1,103

Total revenue - 3,160 4,944

Operating Expenses:

Research and development 7,085 6,941 96,819

General and administrative 2,850 5,186 43,256

Impairment
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable plastics ... low carbon footprints and compostability. These properties can help in limiting the degradation ... basis of applications, the market for biodegradable plastics can be broadly segmented into ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) ... & Africa Biomedical Sensors Market - Growth, Trends & ... The Middle East & ... by 2018 at a CAGR of 3.26% over the ... Biomedical sensors that are adaptable to the genetic formulation ...
(Date:8/31/2015)... and SHANGHAI , Aug. ... biopharmaceutical company developing next-generation antibiotics, today announced positive ... study for its lead drug candidate MRX-I. MRX-I ... drug-resistant bacteria such as MRSA and VRE, while ... tolerated therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Food Processing Suppliers ... beverage processors, equipment manufacturers and leaders in the field of academia. , ... formulation for manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; ...
Breaking Biology Technology:Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... CRY ),a biomaterials, medical device and tissue ... 2008 Cardiac Allograft Symposium at its,corporate headquarters training ... will focus on current clinical outcomes, indications and,surgical ... the CryoValve(R) SG pulmonary human heart valves., ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today ... controlling interest in Jiangsu,Institute of Microbiology Co., Ltd. ... the People,s Republic of China. JSIM,has several drugs ... its development pipeline. This acquisition is expected to ...
... United,Therapeutics Corporation (Nasdaq: UTHR ) announced today ... results before the open of market,on Thursday, May ... half-hour teleconference on Thursday,May 1, 2008, at 9:00 ... 1-800-603-1777, with international callers dialing 1-706-679-8129.,A rebroadcast of ...
Cached Biology Technology:CryoLife Conducts Surgeons Cardiac Allograft Symposium 2Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 27 SAFC®, a member of the Sigma-Aldrich® Group ... investment program to expand its Lenexa, KS , ... seamless upstream and downstream production of dry powder media and ... designed to better serve the biopharmaceutical industry by creating ,Centers ...
... , April 27 Negotiations broke off early Tuesday morning between ... Professionals (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, ... , , ...
... MDC ) today announced that its board of directors has declared a regular quarterly ... common stock.  The dividend will be paid on Wednesday, May 26, 2010 to ... , , ... , Since 1972, MDC,s subsidiary ...
Cached Biology News:SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 2SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 3SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 4SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 5M.D.C. Holdings Declares Quarterly Cash Dividend 2
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: